A closer look at depression and its relationship to HIV antiretroviral adherence

Glenn J. Wagner, Kathy Goggin, Robert H. Remien, Marc I. Rosen, Jane Simoni, David Bangsberg, Honghu Liu

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background Depression consistently predicts nonadherence to human immunodeficiency virus antiretroviral therapy, but which aspects of depression are most influential are unknown. Such knowledge could inform assessments of adherence readiness and the type of depression treatment to utilize. Purpose We examined how depression severity, symptom type, and change over time relate to adherence. Methods Microelectronic adherence and self-reported depression data from 1,374 participants across merged studies were examined with cross-sectional and longitudinal analyses. Depression variables included a continuous measure, categorical measure of severity, cognitive and vegetative subscales, and individual symptoms. Results At baseline, mean adherence was 69%, and 25% had mild/moderate and 18% had severe depression. In cross-sectional multivariate analyses, continuous depression, cognitive depressive symptoms, and severe depression were associated with lower adherence. In longitudinal analysis, reductions in both continuous and categorical depression predicted increased adherence. Conclusions The relationship between global continuous depression and nonadherence was statistically significant, but relatively weak compared to that of cognitive depressive symptoms and severe depression, which appear to pose strong challenges to adherence and call for the need for early detection and treatment of depression.

Original languageEnglish (US)
Pages (from-to)352-360
Number of pages9
JournalAnnals of Behavioral Medicine
Volume42
Issue number3
DOIs
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

HIV
Depression
Neurobehavioral Manifestations
Cross-Sectional Studies
Multivariate Analysis

Keywords

  • Antiretroviral adherence
  • Cognitive depressive symptoms
  • Depression
  • HIV/AIDS

ASJC Scopus subject areas

  • Psychology(all)
  • Psychiatry and Mental health

Cite this

A closer look at depression and its relationship to HIV antiretroviral adherence. / Wagner, Glenn J.; Goggin, Kathy; Remien, Robert H.; Rosen, Marc I.; Simoni, Jane; Bangsberg, David; Liu, Honghu.

In: Annals of Behavioral Medicine, Vol. 42, No. 3, 12.2011, p. 352-360.

Research output: Contribution to journalArticle

Wagner, Glenn J. ; Goggin, Kathy ; Remien, Robert H. ; Rosen, Marc I. ; Simoni, Jane ; Bangsberg, David ; Liu, Honghu. / A closer look at depression and its relationship to HIV antiretroviral adherence. In: Annals of Behavioral Medicine. 2011 ; Vol. 42, No. 3. pp. 352-360.
@article{10dc3359ed854b64bd852bc75a8dc411,
title = "A closer look at depression and its relationship to HIV antiretroviral adherence",
abstract = "Background Depression consistently predicts nonadherence to human immunodeficiency virus antiretroviral therapy, but which aspects of depression are most influential are unknown. Such knowledge could inform assessments of adherence readiness and the type of depression treatment to utilize. Purpose We examined how depression severity, symptom type, and change over time relate to adherence. Methods Microelectronic adherence and self-reported depression data from 1,374 participants across merged studies were examined with cross-sectional and longitudinal analyses. Depression variables included a continuous measure, categorical measure of severity, cognitive and vegetative subscales, and individual symptoms. Results At baseline, mean adherence was 69{\%}, and 25{\%} had mild/moderate and 18{\%} had severe depression. In cross-sectional multivariate analyses, continuous depression, cognitive depressive symptoms, and severe depression were associated with lower adherence. In longitudinal analysis, reductions in both continuous and categorical depression predicted increased adherence. Conclusions The relationship between global continuous depression and nonadherence was statistically significant, but relatively weak compared to that of cognitive depressive symptoms and severe depression, which appear to pose strong challenges to adherence and call for the need for early detection and treatment of depression.",
keywords = "Antiretroviral adherence, Cognitive depressive symptoms, Depression, HIV/AIDS",
author = "Wagner, {Glenn J.} and Kathy Goggin and Remien, {Robert H.} and Rosen, {Marc I.} and Jane Simoni and David Bangsberg and Honghu Liu",
year = "2011",
month = "12",
doi = "10.1007/s12160-011-9295-8",
language = "English (US)",
volume = "42",
pages = "352--360",
journal = "Annals of Behavioral Medicine",
issn = "0883-6612",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - A closer look at depression and its relationship to HIV antiretroviral adherence

AU - Wagner, Glenn J.

AU - Goggin, Kathy

AU - Remien, Robert H.

AU - Rosen, Marc I.

AU - Simoni, Jane

AU - Bangsberg, David

AU - Liu, Honghu

PY - 2011/12

Y1 - 2011/12

N2 - Background Depression consistently predicts nonadherence to human immunodeficiency virus antiretroviral therapy, but which aspects of depression are most influential are unknown. Such knowledge could inform assessments of adherence readiness and the type of depression treatment to utilize. Purpose We examined how depression severity, symptom type, and change over time relate to adherence. Methods Microelectronic adherence and self-reported depression data from 1,374 participants across merged studies were examined with cross-sectional and longitudinal analyses. Depression variables included a continuous measure, categorical measure of severity, cognitive and vegetative subscales, and individual symptoms. Results At baseline, mean adherence was 69%, and 25% had mild/moderate and 18% had severe depression. In cross-sectional multivariate analyses, continuous depression, cognitive depressive symptoms, and severe depression were associated with lower adherence. In longitudinal analysis, reductions in both continuous and categorical depression predicted increased adherence. Conclusions The relationship between global continuous depression and nonadherence was statistically significant, but relatively weak compared to that of cognitive depressive symptoms and severe depression, which appear to pose strong challenges to adherence and call for the need for early detection and treatment of depression.

AB - Background Depression consistently predicts nonadherence to human immunodeficiency virus antiretroviral therapy, but which aspects of depression are most influential are unknown. Such knowledge could inform assessments of adherence readiness and the type of depression treatment to utilize. Purpose We examined how depression severity, symptom type, and change over time relate to adherence. Methods Microelectronic adherence and self-reported depression data from 1,374 participants across merged studies were examined with cross-sectional and longitudinal analyses. Depression variables included a continuous measure, categorical measure of severity, cognitive and vegetative subscales, and individual symptoms. Results At baseline, mean adherence was 69%, and 25% had mild/moderate and 18% had severe depression. In cross-sectional multivariate analyses, continuous depression, cognitive depressive symptoms, and severe depression were associated with lower adherence. In longitudinal analysis, reductions in both continuous and categorical depression predicted increased adherence. Conclusions The relationship between global continuous depression and nonadherence was statistically significant, but relatively weak compared to that of cognitive depressive symptoms and severe depression, which appear to pose strong challenges to adherence and call for the need for early detection and treatment of depression.

KW - Antiretroviral adherence

KW - Cognitive depressive symptoms

KW - Depression

KW - HIV/AIDS

UR - http://www.scopus.com/inward/record.url?scp=84857040879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857040879&partnerID=8YFLogxK

U2 - 10.1007/s12160-011-9295-8

DO - 10.1007/s12160-011-9295-8

M3 - Article

C2 - 21818528

AN - SCOPUS:84857040879

VL - 42

SP - 352

EP - 360

JO - Annals of Behavioral Medicine

JF - Annals of Behavioral Medicine

SN - 0883-6612

IS - 3

ER -